Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays

Propranolol is a widely used β-blocker that can generate a nitrosated derivative, N-nitroso propranolol (NNP). NNP has been reported to be negative in the bacterial reverse mutation test (the Ames test) but genotoxic in other in vitro assays. In the current study, we systematically examined the in v...

Full description

Saved in:
Bibliographic Details
Published inRegulatory toxicology and pharmacology Vol. 141; no. C; p. 105410
Main Authors Li, Xilin, Le, Yuan, Seo, Ji-Eun, Guo, Xiaoqing, Li, Yuxi, Chen, Si, Mittelstaedt, Roberta A., Moore, Nyosha, Guerrero, Sharon, Sims, Audrey, King, Sruthi T., Atrakchi, Aisar H., McGovern, Timothy J., Davis-Bruno, Karen L., Keire, David A., Elespuru, Rosalie K., Heflich, Robert H., Mei, Nan
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Inc 01.06.2023
Elsevier
Subjects
Online AccessGet full text
ISSN0273-2300
1096-0295
1096-0295
DOI10.1016/j.yrtph.2023.105410

Cover

Loading…
Abstract Propranolol is a widely used β-blocker that can generate a nitrosated derivative, N-nitroso propranolol (NNP). NNP has been reported to be negative in the bacterial reverse mutation test (the Ames test) but genotoxic in other in vitro assays. In the current study, we systematically examined the in vitro mutagenicity and genotoxicity of NNP using several modifications of the Ames test known to affect the mutagenicity of nitrosamines, as well as a battery of genotoxicity tests using human cells. We found that NNP induced concentration-dependent mutations in the Ames test, both in two tester strains that detect base pair substitutions, TA1535 and TA100, as well as in the TA98 frameshift-detector strain. Although positive results were seen with rat liver S9, the hamster liver S9 fraction was more effective in bio-transforming NNP into a reactive mutagen. NNP also induced micronuclei and gene mutations in human lymphoblastoid TK6 cells in the presence of hamster liver S9. Using a panel of TK6 cell lines that each expresses a different human cytochrome P450 (CYP), CYP2C19 was identified as the most active enzyme in the bioactivation of NNP to a genotoxicant among those tested. NNP also induced concentration-dependent DNA strand breakage in metabolically competent 2-dimensional (2D) and 3D cultures of human HepaRG cells. This study indicates that NNP is genotoxic in a variety of bacterial and mammalian systems. Thus, NNP is a mutagenic and genotoxic nitrosamine and a potential human carcinogen. •NNP induced concentration-dependent mutations in the Ames test in TA98, TA100, and TA1535.•NNP induced micronuclei and gene mutations in TK6 cells in the presence of hamster liver S9.•CYP2C19 was identified as the most active enzyme in the bioactivation of NNP.•NNP induced concentration-dependent DNA strand breakage in metabolically competent human HepaRG cells.
AbstractList Propranolol is a widely used β-blocker that can generate a nitrosated derivative, N-nitroso propranolol (NNP). NNP has been reported to be negative in the bacterial reverse mutation test (the Ames test) but genotoxic in other in vitro assays. In the current study, we systematically examined the in vitro mutagenicity and genotoxicity of NNP using several modifications of the Ames test known to affect the mutagenicity of nitrosamines, as well as a battery of genotoxicity tests using human cells. We found that NNP induced concentration-dependent mutations in the Ames test, both in two tester strains that detect base pair substitutions, TA1535 and TA100, as well as in the TA98 frameshift-detector strain. Although positive results were seen with rat liver S9, the hamster liver S9 fraction was more effective in bio-transforming NNP into a reactive mutagen. NNP also induced micronuclei and gene mutations in human lymphoblastoid TK6 cells in the presence of hamster liver S9. Using a panel of TK6 cell lines that each expresses a different human cytochrome P450 (CYP), CYP2C19 was identified as the most active enzyme in the bioactivation of NNP to a genotoxicant among those tested. NNP also induced concentration-dependent DNA strand breakage in metabolically competent 2-dimensional (2D) and 3D cultures of human HepaRG cells. This study indicates that NNP is genotoxic in a variety of bacterial and mammalian systems. Thus, NNP is a mutagenic and genotoxic nitrosamine and a potential human carcinogen.
Not provided.
Propranolol is a widely used β-blocker that can generate a nitrosated derivative, N-nitroso propranolol (NNP). NNP has been reported to be negative in the bacterial reverse mutation test (the Ames test) but genotoxic in other in vitro assays. In the current study, we systematically examined the in vitro mutagenicity and genotoxicity of NNP using several modifications of the Ames test known to affect the mutagenicity of nitrosamines, as well as a battery of genotoxicity tests using human cells. We found that NNP induced concentration-dependent mutations in the Ames test, both in two tester strains that detect base pair substitutions, TA1535 and TA100, as well as in the TA98 frameshift-detector strain. Although positive results were seen with rat liver S9, the hamster liver S9 fraction was more effective in bio-transforming NNP into a reactive mutagen. NNP also induced micronuclei and gene mutations in human lymphoblastoid TK6 cells in the presence of hamster liver S9. Using a panel of TK6 cell lines that each expresses a different human cytochrome P450 (CYP), CYP2C19 was identified as the most active enzyme in the bioactivation of NNP to a genotoxicant among those tested. NNP also induced concentration-dependent DNA strand breakage in metabolically competent 2-dimensional (2D) and 3D cultures of human HepaRG cells. This study indicates that NNP is genotoxic in a variety of bacterial and mammalian systems. Thus, NNP is a mutagenic and genotoxic nitrosamine and a potential human carcinogen. •NNP induced concentration-dependent mutations in the Ames test in TA98, TA100, and TA1535.•NNP induced micronuclei and gene mutations in TK6 cells in the presence of hamster liver S9.•CYP2C19 was identified as the most active enzyme in the bioactivation of NNP.•NNP induced concentration-dependent DNA strand breakage in metabolically competent human HepaRG cells.
Propranolol is a widely used β-blocker that can generate a nitrosated derivative, N-nitroso propranolol (NNP). NNP has been reported to be negative in the bacterial reverse mutation test (the Ames test) but genotoxic in other in vitro assays. In the current study, we systematically examined the in vitro mutagenicity and genotoxicity of NNP using several modifications of the Ames test known to affect the mutagenicity of nitrosamines, as well as a battery of genotoxicity tests using human cells. We found that NNP induced concentration-dependent mutations in the Ames test, both in two tester strains that detect base pair substitutions, TA1535 and TA100, as well as in the TA98 frameshift-detector strain. Although positive results were seen with rat liver S9, the hamster liver S9 fraction was more effective in bio-transforming NNP into a reactive mutagen. NNP also induced micronuclei and gene mutations in human lymphoblastoid TK6 cells in the presence of hamster liver S9. Using a panel of TK6 cell lines that each expresses a different human cytochrome P450 (CYP), CYP2C19 was identified as the most active enzyme in the bioactivation of NNP to a genotoxicant among those tested. NNP also induced concentration-dependent DNA strand breakage in metabolically competent 2-dimensional (2D) and 3D cultures of human HepaRG cells. This study indicates that NNP is genotoxic in a variety of bacterial and mammalian systems. Thus, NNP is a mutagenic and genotoxic nitrosamine and a potential human carcinogen.Propranolol is a widely used β-blocker that can generate a nitrosated derivative, N-nitroso propranolol (NNP). NNP has been reported to be negative in the bacterial reverse mutation test (the Ames test) but genotoxic in other in vitro assays. In the current study, we systematically examined the in vitro mutagenicity and genotoxicity of NNP using several modifications of the Ames test known to affect the mutagenicity of nitrosamines, as well as a battery of genotoxicity tests using human cells. We found that NNP induced concentration-dependent mutations in the Ames test, both in two tester strains that detect base pair substitutions, TA1535 and TA100, as well as in the TA98 frameshift-detector strain. Although positive results were seen with rat liver S9, the hamster liver S9 fraction was more effective in bio-transforming NNP into a reactive mutagen. NNP also induced micronuclei and gene mutations in human lymphoblastoid TK6 cells in the presence of hamster liver S9. Using a panel of TK6 cell lines that each expresses a different human cytochrome P450 (CYP), CYP2C19 was identified as the most active enzyme in the bioactivation of NNP to a genotoxicant among those tested. NNP also induced concentration-dependent DNA strand breakage in metabolically competent 2-dimensional (2D) and 3D cultures of human HepaRG cells. This study indicates that NNP is genotoxic in a variety of bacterial and mammalian systems. Thus, NNP is a mutagenic and genotoxic nitrosamine and a potential human carcinogen.
ArticleNumber 105410
Author Moore, Nyosha
Mittelstaedt, Roberta A.
Elespuru, Rosalie K.
Le, Yuan
Keire, David A.
Sims, Audrey
Heflich, Robert H.
Chen, Si
Seo, Ji-Eun
Davis-Bruno, Karen L.
Li, Xilin
Guo, Xiaoqing
Mei, Nan
Li, Yuxi
Guerrero, Sharon
Atrakchi, Aisar H.
King, Sruthi T.
McGovern, Timothy J.
Author_xml – sequence: 1
  givenname: Xilin
  surname: Li
  fullname: Li, Xilin
  email: xilin.li@fda.hhs.gov
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 2
  givenname: Yuan
  surname: Le
  fullname: Le, Yuan
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 3
  givenname: Ji-Eun
  surname: Seo
  fullname: Seo, Ji-Eun
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 4
  givenname: Xiaoqing
  surname: Guo
  fullname: Guo, Xiaoqing
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 5
  givenname: Yuxi
  surname: Li
  fullname: Li, Yuxi
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 6
  givenname: Si
  surname: Chen
  fullname: Chen, Si
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 7
  givenname: Roberta A.
  surname: Mittelstaedt
  fullname: Mittelstaedt, Roberta A.
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 8
  givenname: Nyosha
  surname: Moore
  fullname: Moore, Nyosha
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 9
  givenname: Sharon
  surname: Guerrero
  fullname: Guerrero, Sharon
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 10
  givenname: Audrey
  surname: Sims
  fullname: Sims, Audrey
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 11
  givenname: Sruthi T.
  surname: King
  fullname: King, Sruthi T.
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA
– sequence: 12
  givenname: Aisar H.
  surname: Atrakchi
  fullname: Atrakchi, Aisar H.
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA
– sequence: 13
  givenname: Timothy J.
  surname: McGovern
  fullname: McGovern, Timothy J.
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA
– sequence: 14
  givenname: Karen L.
  surname: Davis-Bruno
  fullname: Davis-Bruno, Karen L.
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA
– sequence: 15
  givenname: David A.
  surname: Keire
  fullname: Keire, David A.
  organization: Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, 20993, USA
– sequence: 16
  givenname: Rosalie K.
  surname: Elespuru
  fullname: Elespuru, Rosalie K.
  organization: Discovery Life Sciences, Columbia, MD, 21045, USA
– sequence: 17
  givenname: Robert H.
  surname: Heflich
  fullname: Heflich, Robert H.
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
– sequence: 18
  givenname: Nan
  orcidid: 0000-0002-3501-9014
  surname: Mei
  fullname: Mei, Nan
  email: nan.mei@fda.hhs.gov
  organization: National Center for Toxicological Research, U.S. Food and Drug Administration, Jefferson, AR, 72079, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37210026$$D View this record in MEDLINE/PubMed
https://www.osti.gov/biblio/2425788$$D View this record in Osti.gov
BookMark eNp9kctuFDEQRS0URCaBL0BCFis2PfjRzwULFPGSIpBQ9laNXc541G0PtnvE_D3udLJhkZVdpXPLvnWvyIUPHgl5y9mWM95-PGzPMR_3W8GELJ2m5uwF2XA2tBUTQ3NBNkx0shKSsUtyldKBMSb6vntFLmUneCnaDRl_48kll52_p3mPdJoz3KN32uUzBW9oKUIOf9dGsPRn5V2OIQV6jOEYwYcxjNR5ugOdMToYH2T7eQK_tE8LTSElOKfX5KWFMeGbx_Oa3H39cnfzvbr99e3HzefbSteS50oOAixYabRomrbWYtf0TJbr0LWDsXawOytAm6ZQNTO1bbsBmh4NY1Dsy2vyfh0bUnYqlZ-j3uvgPeqsRC2aru8L9GGFio0_M6asJpc0jiN4DHNSoudt1_JOLvPePaLzbkKjjtFNEM_qaYsFGFZAl8WkiFaVNyG74HMENyrO1JKYOqiHxNSSmFoTK1r5n_Zp_POqT6sKyxpPDuNiE71G4-Li0gT3rP4fLiCx8w
CitedBy_id crossref_primary_10_1002_slct_202404146
crossref_primary_10_1016_j_yrtph_2024_105762
crossref_primary_10_1016_j_yrtph_2024_105640
crossref_primary_10_1002_cpz1_1003
crossref_primary_10_1002_em_70007
crossref_primary_10_1016_j_toxlet_2024_01_012
crossref_primary_10_1016_j_yrtph_2024_105730
crossref_primary_10_1016_j_yrtph_2024_105763
crossref_primary_10_1021_acs_chemrestox_4c00234
crossref_primary_10_1038_s41598_024_72283_5
crossref_primary_10_1016_j_xphs_2023_10_001
crossref_primary_10_1007_s00204_024_03859_3
crossref_primary_10_1016_j_toxrep_2024_01_012
crossref_primary_10_1016_j_yrtph_2024_105709
crossref_primary_10_1021_acs_oprd_3c00153
crossref_primary_10_1080_26896583_2024_2331956
Cites_doi 10.1016/0041-008X(89)90253-6
10.1021/jm00357a027
10.1016/j.comtox.2021.100186
10.1016/0378-4274(94)90057-4
10.1517/17425251003674380
10.1016/S0027-5107(01)00223-8
10.1016/j.xphs.2022.11.013
10.1016/j.mrrev.2006.09.003
10.1016/0027-5107(77)90151-8
10.3389/fphar.2016.00443
10.1093/mutage/10.6.517
10.1016/j.yrtph.2022.105247
10.1002/em.22028
10.3389/ftox.2022.864753
10.1081/DCT-120024844
10.1007/s00204-019-02406-9
10.1038/225021a0
10.1016/j.jpeds.2014.08.067
10.1002/em.21996
10.1002/em.2860040103
10.1016/j.mrgentox.2021.503351
10.2174/1389200221666200414094644
10.1016/S0065-230X(08)60079-2
10.1016/0165-1110(88)90023-1
10.1081/DMR-120005668
10.1093/carcin/17.9.2029
10.1016/0027-5107(87)90019-4
10.1093/toxsci/kfaa035
10.1016/0027-5107(83)90058-1
10.1093/carcin/13.10.1789
10.1016/j.jpba.2017.10.035
10.1016/j.fct.2020.111662
10.1007/s00204-022-03347-6
10.1093/mutage/geab039
10.1093/mutage/gev085
10.1016/j.jhazmat.2010.09.062
10.1016/0165-1161(94)90037-X
10.1016/j.mrgentox.2007.03.002
ContentType Journal Article
Copyright 2023
Published by Elsevier Inc.
Copyright_xml – notice: 2023
– notice: Published by Elsevier Inc.
CorporateAuthor Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN (United States)
CorporateAuthor_xml – name: Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN (United States)
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
OTOTI
DOI 10.1016/j.yrtph.2023.105410
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
OSTI.GOV
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
Pharmacy, Therapeutics, & Pharmacology
EISSN 1096-0295
ExternalDocumentID 2425788
37210026
10_1016_j_yrtph_2023_105410
S0273230023000788
Genre Journal Article
GrantInformation_xml – fundername: Intramural FDA HHS
  grantid: FD999999
GroupedDBID ---
--K
--M
.~1
0R~
123
1B1
1RT
1~.
1~5
29P
4.4
457
4G.
53G
5VS
7-5
71M
8P~
9JM
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATCM
AAXUO
ABEFU
ABFYP
ABJNI
ABLST
ABMAC
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFS
ACRLP
ADBBV
ADEZE
ADFGL
ADMUD
AEBSH
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHEUO
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AKIFW
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLECG
BLXMC
C45
CAG
COF
CS3
DM4
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F3I
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMT
HVGLF
HZ~
IHE
J1W
KCYFY
KOM
LG5
M33
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SPT
SSJ
SSP
SSZ
T5K
TEORI
UHS
WUQ
XPP
ZGI
ZMT
ZU3
ZXP
~G-
~KM
AAHBH
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGCQF
AGQPQ
AGRNS
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
BNPGV
CITATION
SSH
CGR
CUY
CVF
ECM
EFKBS
EIF
NPM
7X8
OTOTI
ID FETCH-LOGICAL-c431t-392afaf3dc25564c2b58035569769dff9fbf2acd5afa40d4f679a58ed00a1093
IEDL.DBID .~1
ISSN 0273-2300
1096-0295
IngestDate Mon Aug 26 10:21:52 EDT 2024
Mon Jul 21 09:27:10 EDT 2025
Mon Jul 21 06:07:02 EDT 2025
Tue Jul 01 02:41:58 EDT 2025
Thu Apr 24 23:09:53 EDT 2025
Fri Feb 23 02:35:18 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue C
Keywords Cytochrome P450s
Hamster liver S9
Chromosomal damage
Nitrosamine impurities
Gene mutation
N-Nitroso propranolol
Language English
License Published by Elsevier Inc.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c431t-392afaf3dc25564c2b58035569769dff9fbf2acd5afa40d4f679a58ed00a1093
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
SC0014664
USDOE Office of Science (SC)
ORCID 0000-0002-3501-9014
0000000235019014
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/11393638
PMID 37210026
PQID 2816761739
PQPubID 23479
ParticipantIDs osti_scitechconnect_2425788
proquest_miscellaneous_2816761739
pubmed_primary_37210026
crossref_citationtrail_10_1016_j_yrtph_2023_105410
crossref_primary_10_1016_j_yrtph_2023_105410
elsevier_sciencedirect_doi_10_1016_j_yrtph_2023_105410
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate June 2023
2023-06-00
2023-Jun
20230601
2023-06-01
PublicationDateYYYYMMDD 2023-06-01
PublicationDate_xml – month: 06
  year: 2023
  text: June 2023
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
– name: United States
PublicationTitle Regulatory toxicology and pharmacology
PublicationTitleAlternate Regul Toxicol Pharmacol
PublicationYear 2023
Publisher Elsevier Inc
Elsevier
Publisher_xml – name: Elsevier Inc
– name: Elsevier
References Bryce (bib8) 2007; 630
Lijinsky, Andrews (bib27) 1983; 111
OECD (bib36) 2020
FDA, 2018. M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk.
Callander (bib10) 1995; 10
ICH (bib18) 2017
Kikugawa (bib22) 1987; 177
Masubuchi (bib32) 1994; 22
OECD (bib35) 2016
Brambilla, Martelli (bib6) 2007; 635
Chen (bib13) 2022; 4
Gatehouse (bib17) 1994; 312
Ishidate (bib19) 1988; 195
Berger (bib4) 2016; 7
O'Neill (bib34) 1982; 4
Magee, Barnes (bib30) 1967; 10
Raisfeld-Danse, Chen (bib39) 1983; 225
Cross, Ponting (bib14) 2021; 20
Ozhan, Alpertunga (bib37) 2003; 26
Canada (bib11) 2022
Seo (bib42) 2022; 39
Preussmann (bib38) 1984
Martelli (bib31) 1994; 73
Kalam (bib20) 2020; 21
Wills (bib46) 2016; 31
Yahagi (bib47) 1977; 48
Chen (bib12) 2021; 39
Kamataki (bib21) 2002; 34
(Accessed 2 May 2023).
Seo (bib43) 2019; 93
Zhang (bib49) 1983; 26
Bryce (bib9) 2016; 57
Robbiano (bib40) 1991; 51
Brambilla (bib7) 1989; 97
Lijinsky, Epstein (bib28) 1970; 225
Li (bib24) 2020; 175
Bellec (bib3) 1996; 17
Li (bib26) 2022; 96
Sluggett (bib44) 2018; 149
Trejo-Martin (bib45) 2022; 135
Liviac (bib29) 2011; 185
Fujita, Kamataki (bib16) 2001; 483
Lewis, Ito (bib23) 2010; 6
Li (bib25) 2020; 145
Bernacki (bib5) 2016; 57
Mittelstaedt (bib33) 2021; 866
Yamazaki (bib48) 1992; 13
Barton (bib2) 2015; 166
Avlasevich (bib1) 2021; 36
Schlingemann (bib41) 2023; 112
Raisfeld-Danse (10.1016/j.yrtph.2023.105410_bib39) 1983; 225
Kikugawa (10.1016/j.yrtph.2023.105410_bib22) 1987; 177
Bryce (10.1016/j.yrtph.2023.105410_bib9) 2016; 57
Trejo-Martin (10.1016/j.yrtph.2023.105410_bib45) 2022; 135
Cross (10.1016/j.yrtph.2023.105410_bib14) 2021; 20
Robbiano (10.1016/j.yrtph.2023.105410_bib40) 1991; 51
Masubuchi (10.1016/j.yrtph.2023.105410_bib32) 1994; 22
Ishidate (10.1016/j.yrtph.2023.105410_bib19) 1988; 195
O'Neill (10.1016/j.yrtph.2023.105410_bib34) 1982; 4
Bernacki (10.1016/j.yrtph.2023.105410_bib5) 2016; 57
Brambilla (10.1016/j.yrtph.2023.105410_bib7) 1989; 97
Lewis (10.1016/j.yrtph.2023.105410_bib23) 2010; 6
Li (10.1016/j.yrtph.2023.105410_bib25) 2020; 145
Sluggett (10.1016/j.yrtph.2023.105410_bib44) 2018; 149
Callander (10.1016/j.yrtph.2023.105410_bib10) 1995; 10
Bellec (10.1016/j.yrtph.2023.105410_bib3) 1996; 17
10.1016/j.yrtph.2023.105410_bib15
Chen (10.1016/j.yrtph.2023.105410_bib12) 2021; 39
Ozhan (10.1016/j.yrtph.2023.105410_bib37) 2003; 26
Magee (10.1016/j.yrtph.2023.105410_bib30) 1967; 10
Liviac (10.1016/j.yrtph.2023.105410_bib29) 2011; 185
Lijinsky (10.1016/j.yrtph.2023.105410_bib27) 1983; 111
OECD (10.1016/j.yrtph.2023.105410_bib36)
Schlingemann (10.1016/j.yrtph.2023.105410_bib41) 2023; 112
Li (10.1016/j.yrtph.2023.105410_bib26) 2022; 96
Yahagi (10.1016/j.yrtph.2023.105410_bib47) 1977; 48
ICH (10.1016/j.yrtph.2023.105410_bib18)
Berger (10.1016/j.yrtph.2023.105410_bib4) 2016; 7
Kamataki (10.1016/j.yrtph.2023.105410_bib21) 2002; 34
Canada (10.1016/j.yrtph.2023.105410_bib11)
Martelli (10.1016/j.yrtph.2023.105410_bib31) 1994; 73
Brambilla (10.1016/j.yrtph.2023.105410_bib6) 2007; 635
Seo (10.1016/j.yrtph.2023.105410_bib43) 2019; 93
Chen (10.1016/j.yrtph.2023.105410_bib13) 2022; 4
Fujita (10.1016/j.yrtph.2023.105410_bib16) 2001; 483
OECD (10.1016/j.yrtph.2023.105410_bib35)
Seo (10.1016/j.yrtph.2023.105410_bib42) 2022; 39
Gatehouse (10.1016/j.yrtph.2023.105410_bib17) 1994; 312
Barton (10.1016/j.yrtph.2023.105410_bib2) 2015; 166
Yamazaki (10.1016/j.yrtph.2023.105410_bib48) 1992; 13
Preussmann (10.1016/j.yrtph.2023.105410_bib38) 1984
Wills (10.1016/j.yrtph.2023.105410_bib46) 2016; 31
Mittelstaedt (10.1016/j.yrtph.2023.105410_bib33) 2021; 866
Li (10.1016/j.yrtph.2023.105410_bib24) 2020; 175
Zhang (10.1016/j.yrtph.2023.105410_bib49) 1983; 26
Lijinsky (10.1016/j.yrtph.2023.105410_bib28) 1970; 225
Bryce (10.1016/j.yrtph.2023.105410_bib8) 2007; 630
Kalam (10.1016/j.yrtph.2023.105410_bib20) 2020; 21
Avlasevich (10.1016/j.yrtph.2023.105410_bib1) 2021; 36
References_xml – volume: 175
  start-page: 251
  year: 2020
  end-page: 265
  ident: bib24
  article-title: Development and application of TK6-derived cells expressing human cytochrome P450s for genotoxicity testing
  publication-title: Toxicol. Sci.
– year: 2022
  ident: bib11
  article-title: Health product recall. Government of Canada
– volume: 630
  start-page: 78
  year: 2007
  end-page: 91
  ident: bib8
  article-title: In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity
  publication-title: Mutat. Res.
– volume: 39
  start-page: 68
  year: 2021
  end-page: 86
  ident: bib12
  article-title: Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
  publication-title: J. Environ. Sci. Health C Toxicol. Carcinog.
– volume: 34
  start-page: 667
  year: 2002
  end-page: 676
  ident: bib21
  article-title: Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP
  publication-title: Drug Metab. Rev.
– volume: 111
  start-page: 135
  year: 1983
  end-page: 144
  ident: bib27
  article-title: The superiority of hamster liver microsomal fraction for activating nitrosamines to mutagens in Salmonella typhimurium
  publication-title: Mutat. Res.
– volume: 866
  start-page: 503351
  year: 2021
  ident: bib33
  article-title: Differentiating between micronucleus dose-responses induced by whole cigarette smoke solutions with Benchmark Dose potency ranking
  publication-title: Mutat. Res. Genet. Toxicol. Environ. Mutagen
– year: 2016
  ident: bib35
  article-title: OECD guideline for the testing of chemicals, section 4
– volume: 20
  start-page: 100186
  year: 2021
  ident: bib14
  article-title: Developing structure-activity relationships for N-nitrosamine activity
  publication-title: Comput. Toxicol.
– start-page: 3
  year: 1984
  end-page: 15
  ident: bib38
  article-title: Occurrence and exposure to N-nitroso compounds and precursors
  publication-title: IARC Sci. Publ.
– volume: 13
  start-page: 1789
  year: 1992
  end-page: 1794
  ident: bib48
  article-title: Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes
  publication-title: Carcinogenesis
– volume: 36
  start-page: 407
  year: 2021
  end-page: 418
  ident: bib1
  article-title: Biomarkers of DNA damage response improve in vitro micronucleus assays by revealing genotoxic mode of action and reducing the occurrence of irrelevant positive results
  publication-title: Mutagenesis
– year: 2017
  ident: bib18
  article-title: Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk M7(R1)
– volume: 10
  start-page: 517
  year: 1995
  end-page: 522
  ident: bib10
  article-title: Evaluation of phenobarbital/beta-naphthoflavone as an alternative S9-induction regime to Aroclor 1254 in the rat for use in in vitro genotoxicity assays
  publication-title: Mutagenesis
– volume: 73
  start-page: 185
  year: 1994
  end-page: 191
  ident: bib31
  article-title: Low clastogenic activity in vivo of the N-nitroso derivatives of 5 beta-adrenergic-blocking drugs proved to be potent genotoxins in vitro
  publication-title: Toxicol. Lett.
– reference: . (Accessed 2 May 2023).
– volume: 195
  start-page: 151
  year: 1988
  end-page: 213
  ident: bib19
  article-title: A comparative analysis of data on the clastogenicity of 951 chemical substances tested in mammalian cell cultures
  publication-title: Mutat. Res.
– volume: 635
  start-page: 17
  year: 2007
  end-page: 52
  ident: bib6
  article-title: Genotoxic and carcinogenic risk to humans of drug-nitrite interaction products
  publication-title: Mutat. Res.
– volume: 6
  start-page: 661
  year: 2010
  end-page: 674
  ident: bib23
  article-title: Human CYPs involved in drug metabolism: structures, substrates and binding affinities
  publication-title: Expet Opin. Drug Metabol. Toxicol.
– volume: 4
  start-page: 864753
  year: 2022
  ident: bib13
  article-title: Thymidine kinase(+/-) mammalian cell mutagenicity assays for assessment of nanomaterials
  publication-title: Front Toxicol.
– volume: 135
  start-page: 105247
  year: 2022
  ident: bib45
  article-title: Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines
  publication-title: Regul. Toxicol. Pharmacol.
– volume: 21
  start-page: 89
  year: 2020
  end-page: 105
  ident: bib20
  article-title: Clinical pharmacokinetics of propranolot hydrochloride: a review
  publication-title: Curr. Drug Metabol.
– reference: FDA, 2018. M7(R1) assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk.
– volume: 97
  start-page: 480
  year: 1989
  end-page: 488
  ident: bib7
  article-title: Genotoxicity of N-nitrosochlordiazepoxide in cultured mammalian cells
  publication-title: Toxicol. Appl. Pharmacol.
– volume: 57
  start-page: 171
  year: 2016
  end-page: 189
  ident: bib9
  article-title: Genotoxic mode of action predictions from a multiplexed flow cytometric assay and a machine learning approach
  publication-title: Environ. Mol. Mutagen.
– volume: 312
  start-page: 217
  year: 1994
  end-page: 233
  ident: bib17
  article-title: Recommendations for the performance of bacterial mutation assays
  publication-title: Mutat. Res.
– volume: 149
  start-page: 206
  year: 2018
  end-page: 213
  ident: bib44
  article-title: Artifactual degradation of secondary amine-containing drugs during accelerated stability testing when saturated sodium nitrite solutions are used for humidity control
  publication-title: J. Pharm. Biomed. Anal.
– volume: 225
  start-page: 713
  year: 1983
  end-page: 719
  ident: bib39
  article-title: Drug interactions. III. Formation of nitrosamines from therapeutic drugs. Formation, mutagenic properties and safety assessment of propranolol hydrochloride with respect to the intragastric formation of N-nitrosopropranolol under conditions found in patients
  publication-title: J. Pharmacol. Exp. Therapeut.
– volume: 48
  start-page: 121
  year: 1977
  end-page: 129
  ident: bib47
  article-title: Mutagenicities of N-nitrosamines on Salmonella
  publication-title: Mutat. Res.
– volume: 7
  start-page: 443
  year: 2016
  ident: bib4
  article-title: Comparison of liver cell models using the basel phenotyping cocktail
  publication-title: Front. Pharmacol.
– volume: 31
  start-page: 255
  year: 2016
  end-page: 263
  ident: bib46
  article-title: Empirical analysis of BMD metrics in genetic toxicology part I: in vitro analyses to provide robust potency rankings and support MOA determinations
  publication-title: Mutagenesis
– volume: 26
  start-page: 455
  year: 1983
  end-page: 458
  ident: bib49
  article-title: Derivatives of beta-adrenergic antagonists. N-nitrosopropranolol and N-hydroxypropranolol and its aldonitrone
  publication-title: J. Med. Chem.
– volume: 225
  start-page: 21
  year: 1970
  end-page: 23
  ident: bib28
  article-title: Nitrosamines as environmental carcinogens
  publication-title: Nature
– volume: 185
  start-page: 613
  year: 2011
  end-page: 618
  ident: bib29
  article-title: Genotoxic evaluation of the non-halogenated disinfection by-products nitrosodimethylamine and nitrosodiethylamine
  publication-title: J. Hazard Mater.
– volume: 10
  start-page: 163
  year: 1967
  end-page: 246
  ident: bib30
  article-title: Carcinogenic nitroso compounds
  publication-title: Adv. Cancer Res.
– volume: 51
  start-page: 2273
  year: 1991
  end-page: 2279
  ident: bib40
  article-title: Formation of the N-nitroso derivatives of six beta-adrenergic-blocking agents and their genotoxic effects in rat and human hepatocytes
  publication-title: Cancer Res.
– volume: 26
  start-page: 295
  year: 2003
  end-page: 308
  ident: bib37
  article-title: Genotoxic activities of drug-nitrite interaction products
  publication-title: Drug Chem. Toxicol.
– year: 2020
  ident: bib36
  article-title: Bacterial reverse mutation test, OECD test guideline No. 471
– volume: 93
  start-page: 1433
  year: 2019
  end-page: 1448
  ident: bib43
  article-title: Quantitative comparison of in vitro genotoxicity between metabolically competent HepaRG cells and HepG2 cells using the high-throughput high-content CometChip assay
  publication-title: Arch. Toxicol.
– volume: 166
  start-page: 115
  year: 2015
  end-page: 118
  ident: bib2
  article-title: Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrhythmias
  publication-title: J. Pediatr.
– volume: 22
  start-page: 909
  year: 1994
  end-page: 915
  ident: bib32
  article-title: Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase
  publication-title: Drug Metab. Dispos.
– volume: 96
  start-page: 3077
  year: 2022
  end-page: 3089
  ident: bib26
  article-title: Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s
  publication-title: Arch. Toxicol.
– volume: 17
  start-page: 2029
  year: 1996
  end-page: 2034
  ident: bib3
  article-title: Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes
  publication-title: Carcinogenesis
– volume: 177
  start-page: 35
  year: 1987
  end-page: 43
  ident: bib22
  article-title: Formation of a higly mutagenic diazo compound from the bamethan-nitrite reaction
  publication-title: Mutat. Res. Fund Mol. Mech. Mutagen
– volume: 145
  start-page: 111662
  year: 2020
  ident: bib25
  article-title: Evaluation of pyrrolizidine alkaloid-induced genotoxicity using metabolically competent TK6 cell lines
  publication-title: Food Chem. Toxicol.
– volume: 57
  start-page: 546
  year: 2016
  end-page: 558
  ident: bib5
  article-title: γH2AX and p53 responses in TK6 cells discriminate promutagens and nongenotoxicants in the presence of rat liver S9
  publication-title: Environ. Mol. Mutagen.
– volume: 4
  start-page: 7
  year: 1982
  end-page: 18
  ident: bib34
  article-title: Cytotoxicity and mutagenicity of dimethylnitrosamine in mammalian cells (CHO/HGPRT system); enhancement by calcium phosphate
  publication-title: Environ. Mutagen.
– volume: 483
  start-page: 35
  year: 2001
  end-page: 41
  ident: bib16
  article-title: Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase
  publication-title: Mutat. Res.
– volume: 112
  start-page: 1287
  year: 2023
  end-page: 1304
  ident: bib41
  article-title: The landscape of potential small and drug substance related nitrosamines in pharmaceuticals
  publication-title: J. Pharmaceut. Sci.
– volume: 39
  start-page: 583
  year: 2022
  end-page: 604
  ident: bib42
  article-title: Evaluation of an in vitro three-dimensional HepaRG spheroid model for genotoxicity testing using the high-throughput CometChip platform
  publication-title: ALTEX
– volume: 97
  start-page: 480
  year: 1989
  ident: 10.1016/j.yrtph.2023.105410_bib7
  article-title: Genotoxicity of N-nitrosochlordiazepoxide in cultured mammalian cells
  publication-title: Toxicol. Appl. Pharmacol.
  doi: 10.1016/0041-008X(89)90253-6
– ident: 10.1016/j.yrtph.2023.105410_bib15
– volume: 26
  start-page: 455
  year: 1983
  ident: 10.1016/j.yrtph.2023.105410_bib49
  article-title: Derivatives of beta-adrenergic antagonists. N-nitrosopropranolol and N-hydroxypropranolol and its aldonitrone
  publication-title: J. Med. Chem.
  doi: 10.1021/jm00357a027
– volume: 39
  start-page: 68
  year: 2021
  ident: 10.1016/j.yrtph.2023.105410_bib12
  article-title: Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity
  publication-title: J. Environ. Sci. Health C Toxicol. Carcinog.
– volume: 20
  start-page: 100186
  year: 2021
  ident: 10.1016/j.yrtph.2023.105410_bib14
  article-title: Developing structure-activity relationships for N-nitrosamine activity
  publication-title: Comput. Toxicol.
  doi: 10.1016/j.comtox.2021.100186
– volume: 73
  start-page: 185
  year: 1994
  ident: 10.1016/j.yrtph.2023.105410_bib31
  article-title: Low clastogenic activity in vivo of the N-nitroso derivatives of 5 beta-adrenergic-blocking drugs proved to be potent genotoxins in vitro
  publication-title: Toxicol. Lett.
  doi: 10.1016/0378-4274(94)90057-4
– volume: 6
  start-page: 661
  year: 2010
  ident: 10.1016/j.yrtph.2023.105410_bib23
  article-title: Human CYPs involved in drug metabolism: structures, substrates and binding affinities
  publication-title: Expet Opin. Drug Metabol. Toxicol.
  doi: 10.1517/17425251003674380
– volume: 483
  start-page: 35
  year: 2001
  ident: 10.1016/j.yrtph.2023.105410_bib16
  article-title: Role of human cytochrome P450 (CYP) in the metabolic activation of N-alkylnitrosamines: application of genetically engineered Salmonella typhimurium YG7108 expressing each form of CYP together with human NADPH-cytochrome P450 reductase
  publication-title: Mutat. Res.
  doi: 10.1016/S0027-5107(01)00223-8
– volume: 112
  start-page: 1287
  year: 2023
  ident: 10.1016/j.yrtph.2023.105410_bib41
  article-title: The landscape of potential small and drug substance related nitrosamines in pharmaceuticals
  publication-title: J. Pharmaceut. Sci.
  doi: 10.1016/j.xphs.2022.11.013
– volume: 635
  start-page: 17
  year: 2007
  ident: 10.1016/j.yrtph.2023.105410_bib6
  article-title: Genotoxic and carcinogenic risk to humans of drug-nitrite interaction products
  publication-title: Mutat. Res.
  doi: 10.1016/j.mrrev.2006.09.003
– ident: 10.1016/j.yrtph.2023.105410_bib18
– volume: 48
  start-page: 121
  year: 1977
  ident: 10.1016/j.yrtph.2023.105410_bib47
  article-title: Mutagenicities of N-nitrosamines on Salmonella
  publication-title: Mutat. Res.
  doi: 10.1016/0027-5107(77)90151-8
– volume: 7
  start-page: 443
  year: 2016
  ident: 10.1016/j.yrtph.2023.105410_bib4
  article-title: Comparison of liver cell models using the basel phenotyping cocktail
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2016.00443
– volume: 10
  start-page: 517
  year: 1995
  ident: 10.1016/j.yrtph.2023.105410_bib10
  article-title: Evaluation of phenobarbital/beta-naphthoflavone as an alternative S9-induction regime to Aroclor 1254 in the rat for use in in vitro genotoxicity assays
  publication-title: Mutagenesis
  doi: 10.1093/mutage/10.6.517
– volume: 135
  start-page: 105247
  year: 2022
  ident: 10.1016/j.yrtph.2023.105410_bib45
  article-title: Use of the bacterial reverse mutation assay to predict carcinogenicity of N-nitrosamines
  publication-title: Regul. Toxicol. Pharmacol.
  doi: 10.1016/j.yrtph.2022.105247
– ident: 10.1016/j.yrtph.2023.105410_bib36
– volume: 57
  start-page: 546
  year: 2016
  ident: 10.1016/j.yrtph.2023.105410_bib5
  article-title: γH2AX and p53 responses in TK6 cells discriminate promutagens and nongenotoxicants in the presence of rat liver S9
  publication-title: Environ. Mol. Mutagen.
  doi: 10.1002/em.22028
– start-page: 3
  year: 1984
  ident: 10.1016/j.yrtph.2023.105410_bib38
  article-title: Occurrence and exposure to N-nitroso compounds and precursors
  publication-title: IARC Sci. Publ.
– volume: 39
  start-page: 583
  year: 2022
  ident: 10.1016/j.yrtph.2023.105410_bib42
  article-title: Evaluation of an in vitro three-dimensional HepaRG spheroid model for genotoxicity testing using the high-throughput CometChip platform
  publication-title: ALTEX
– volume: 4
  start-page: 864753
  year: 2022
  ident: 10.1016/j.yrtph.2023.105410_bib13
  article-title: Thymidine kinase(+/-) mammalian cell mutagenicity assays for assessment of nanomaterials
  publication-title: Front Toxicol.
  doi: 10.3389/ftox.2022.864753
– volume: 26
  start-page: 295
  year: 2003
  ident: 10.1016/j.yrtph.2023.105410_bib37
  article-title: Genotoxic activities of drug-nitrite interaction products
  publication-title: Drug Chem. Toxicol.
  doi: 10.1081/DCT-120024844
– volume: 93
  start-page: 1433
  year: 2019
  ident: 10.1016/j.yrtph.2023.105410_bib43
  article-title: Quantitative comparison of in vitro genotoxicity between metabolically competent HepaRG cells and HepG2 cells using the high-throughput high-content CometChip assay
  publication-title: Arch. Toxicol.
  doi: 10.1007/s00204-019-02406-9
– volume: 51
  start-page: 2273
  year: 1991
  ident: 10.1016/j.yrtph.2023.105410_bib40
  article-title: Formation of the N-nitroso derivatives of six beta-adrenergic-blocking agents and their genotoxic effects in rat and human hepatocytes
  publication-title: Cancer Res.
– volume: 225
  start-page: 21
  year: 1970
  ident: 10.1016/j.yrtph.2023.105410_bib28
  article-title: Nitrosamines as environmental carcinogens
  publication-title: Nature
  doi: 10.1038/225021a0
– volume: 166
  start-page: 115
  year: 2015
  ident: 10.1016/j.yrtph.2023.105410_bib2
  article-title: Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrhythmias
  publication-title: J. Pediatr.
  doi: 10.1016/j.jpeds.2014.08.067
– volume: 57
  start-page: 171
  year: 2016
  ident: 10.1016/j.yrtph.2023.105410_bib9
  article-title: Genotoxic mode of action predictions from a multiplexed flow cytometric assay and a machine learning approach
  publication-title: Environ. Mol. Mutagen.
  doi: 10.1002/em.21996
– volume: 4
  start-page: 7
  year: 1982
  ident: 10.1016/j.yrtph.2023.105410_bib34
  article-title: Cytotoxicity and mutagenicity of dimethylnitrosamine in mammalian cells (CHO/HGPRT system); enhancement by calcium phosphate
  publication-title: Environ. Mutagen.
  doi: 10.1002/em.2860040103
– volume: 866
  start-page: 503351
  year: 2021
  ident: 10.1016/j.yrtph.2023.105410_bib33
  article-title: Differentiating between micronucleus dose-responses induced by whole cigarette smoke solutions with Benchmark Dose potency ranking
  publication-title: Mutat. Res. Genet. Toxicol. Environ. Mutagen
  doi: 10.1016/j.mrgentox.2021.503351
– volume: 225
  start-page: 713
  year: 1983
  ident: 10.1016/j.yrtph.2023.105410_bib39
  publication-title: J. Pharmacol. Exp. Therapeut.
– volume: 21
  start-page: 89
  year: 2020
  ident: 10.1016/j.yrtph.2023.105410_bib20
  article-title: Clinical pharmacokinetics of propranolot hydrochloride: a review
  publication-title: Curr. Drug Metabol.
  doi: 10.2174/1389200221666200414094644
– volume: 10
  start-page: 163
  year: 1967
  ident: 10.1016/j.yrtph.2023.105410_bib30
  article-title: Carcinogenic nitroso compounds
  publication-title: Adv. Cancer Res.
  doi: 10.1016/S0065-230X(08)60079-2
– volume: 195
  start-page: 151
  year: 1988
  ident: 10.1016/j.yrtph.2023.105410_bib19
  article-title: A comparative analysis of data on the clastogenicity of 951 chemical substances tested in mammalian cell cultures
  publication-title: Mutat. Res.
  doi: 10.1016/0165-1110(88)90023-1
– volume: 34
  start-page: 667
  year: 2002
  ident: 10.1016/j.yrtph.2023.105410_bib21
  article-title: Role of human cytochrome P450 (CYP) in the metabolic activation of nitrosamine derivatives: application of genetically engineered Salmonella expressing human CYP
  publication-title: Drug Metab. Rev.
  doi: 10.1081/DMR-120005668
– volume: 17
  start-page: 2029
  year: 1996
  ident: 10.1016/j.yrtph.2023.105410_bib3
  article-title: Cytochrome P450 metabolic dealkylation of nine N-nitrosodialkylamines by human liver microsomes
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/17.9.2029
– volume: 177
  start-page: 35
  year: 1987
  ident: 10.1016/j.yrtph.2023.105410_bib22
  article-title: Formation of a higly mutagenic diazo compound from the bamethan-nitrite reaction
  publication-title: Mutat. Res. Fund Mol. Mech. Mutagen
  doi: 10.1016/0027-5107(87)90019-4
– volume: 175
  start-page: 251
  year: 2020
  ident: 10.1016/j.yrtph.2023.105410_bib24
  article-title: Development and application of TK6-derived cells expressing human cytochrome P450s for genotoxicity testing
  publication-title: Toxicol. Sci.
  doi: 10.1093/toxsci/kfaa035
– volume: 111
  start-page: 135
  year: 1983
  ident: 10.1016/j.yrtph.2023.105410_bib27
  article-title: The superiority of hamster liver microsomal fraction for activating nitrosamines to mutagens in Salmonella typhimurium
  publication-title: Mutat. Res.
  doi: 10.1016/0027-5107(83)90058-1
– volume: 13
  start-page: 1789
  year: 1992
  ident: 10.1016/j.yrtph.2023.105410_bib48
  article-title: Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/13.10.1789
– ident: 10.1016/j.yrtph.2023.105410_bib35
– volume: 149
  start-page: 206
  year: 2018
  ident: 10.1016/j.yrtph.2023.105410_bib44
  article-title: Artifactual degradation of secondary amine-containing drugs during accelerated stability testing when saturated sodium nitrite solutions are used for humidity control
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2017.10.035
– volume: 145
  start-page: 111662
  year: 2020
  ident: 10.1016/j.yrtph.2023.105410_bib25
  article-title: Evaluation of pyrrolizidine alkaloid-induced genotoxicity using metabolically competent TK6 cell lines
  publication-title: Food Chem. Toxicol.
  doi: 10.1016/j.fct.2020.111662
– volume: 96
  start-page: 3077
  year: 2022
  ident: 10.1016/j.yrtph.2023.105410_bib26
  article-title: Genotoxicity evaluation of nitrosamine impurities using human TK6 cells transduced with cytochrome P450s
  publication-title: Arch. Toxicol.
  doi: 10.1007/s00204-022-03347-6
– volume: 22
  start-page: 909
  year: 1994
  ident: 10.1016/j.yrtph.2023.105410_bib32
  article-title: Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase
  publication-title: Drug Metab. Dispos.
– volume: 36
  start-page: 407
  year: 2021
  ident: 10.1016/j.yrtph.2023.105410_bib1
  article-title: Biomarkers of DNA damage response improve in vitro micronucleus assays by revealing genotoxic mode of action and reducing the occurrence of irrelevant positive results
  publication-title: Mutagenesis
  doi: 10.1093/mutage/geab039
– volume: 31
  start-page: 255
  year: 2016
  ident: 10.1016/j.yrtph.2023.105410_bib46
  article-title: Empirical analysis of BMD metrics in genetic toxicology part I: in vitro analyses to provide robust potency rankings and support MOA determinations
  publication-title: Mutagenesis
  doi: 10.1093/mutage/gev085
– volume: 185
  start-page: 613
  year: 2011
  ident: 10.1016/j.yrtph.2023.105410_bib29
  article-title: Genotoxic evaluation of the non-halogenated disinfection by-products nitrosodimethylamine and nitrosodiethylamine
  publication-title: J. Hazard Mater.
  doi: 10.1016/j.jhazmat.2010.09.062
– ident: 10.1016/j.yrtph.2023.105410_bib11
– volume: 312
  start-page: 217
  year: 1994
  ident: 10.1016/j.yrtph.2023.105410_bib17
  article-title: Recommendations for the performance of bacterial mutation assays
  publication-title: Mutat. Res.
  doi: 10.1016/0165-1161(94)90037-X
– volume: 630
  start-page: 78
  year: 2007
  ident: 10.1016/j.yrtph.2023.105410_bib8
  article-title: In vitro micronucleus assay scored by flow cytometry provides a comprehensive evaluation of cytogenetic damage and cytotoxicity
  publication-title: Mutat. Res.
  doi: 10.1016/j.mrgentox.2007.03.002
SSID ssj0002887
Score 2.476987
Snippet Propranolol is a widely used β-blocker that can generate a nitrosated derivative, N-nitroso propranolol (NNP). NNP has been reported to be negative in the...
Not provided.
SourceID osti
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 105410
SubjectTerms Animals
Chromosomal damage
Cricetinae
Cytochrome P450s
DNA Damage
Gene mutation
Hamster liver S9
Humans
Legal Medicine
Mammals
Mutagenesis
Mutagenicity Tests - methods
Mutagens - toxicity
Mutation
N-Nitroso propranolol
Nitrosamine impurities
Pharmacology & Pharmacy
Propranolol - toxicity
Rats
Toxicology
Title Revisiting the mutagenicity and genotoxicity of N-nitroso propranolol in bacterial and human in vitro assays
URI https://dx.doi.org/10.1016/j.yrtph.2023.105410
https://www.ncbi.nlm.nih.gov/pubmed/37210026
https://www.proquest.com/docview/2816761739
https://www.osti.gov/biblio/2425788
Volume 141
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED5K9jIYY-t-Zd2KBqNP0WLLsuI8lrKSbSyULYO-CVmyICWzQ-OM5qV_--4ku2Gw9WGPEXfhYp3uPsV33wG8zzECVi7xPEu849LYkhulLM9UlipnRFoGKqWvczX7IT9f5pcHcNb3wlBZZRf7Y0wP0bpbGXdPc7xeLsffiYkFATSBaEp01PBL7HXo0x9u92UeoghD8kiYk2TPPBRqvHbX7ZreSIiM5t1KaqP9e3YaNHjg_g1CQzI6fwKPOxTJTqOhT-Ggqg_h5CLSUO9GbLHvqtqM2Am72BNU7w7hUfyvjsUWpGew-hZazKkAmiEeZD-3LUaZemkRoTNTO0ZErm1zExcaz-YcAwH-gIahpWvMdvjFK7asWRm5n9E0Ugvz_2j5F0kzhOlmt3kOi_OPi7MZ76YwcIvgouUIoIw3PnOW2MqkFWVeJIhSFAKZqfN-6ksvjHU5SsnESa8mU5MX6ACJIa6qFzCom7p6BaxQ3ksi3JO5kEq6okwnxqUmy1UpcquGIPqHr23HUE6DMla6L0W70mHHNO2Yjjs2hNGd0joSdNwvrvpd1X_4mcYUcr_iEfkAKRG7rqUyJNQKN7aiGMK73jU0nk966WLqqtlutChSNUGYmE2H8DL6zJ2dGV6_6RL8-n-NOoKH9CmWrr2BQXu9rd4iSGrL43AKjuHB6acvs_lv4uIRqg
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LaxsxEB5S59BCKU36ctO0KpScLLwPrbw-htDgvExoXchNaKUVOLi7Jl6X-t93Rtp1KDQ59CrPmPFqNPPJO_MNwJcMI2BpI8fTyFkutCm4ltLwVKaxtDqJC0-ldDWVkx_i_Ca72YGTrheGyirb2B9iuo_W7cqwfZrD5Xw-_E5MLAigCURTosufwC6xU4ke7B6fXUym24Cc5H5OHslzEu7Ih3yZ1-auWdJLiSSlkbeCOmn_naB6NZ65h3Goz0enL-FFCyTZcbB1D3bKah-OrgMT9WbAZveNVasBO2LX9xzVm314Hv6uY6EL6RUsvvkuc6qBZggJ2c91g4GmmhsE6UxXlhGXa1P_Dgu1Y1OOsQB_QM3Q0iUmPPziBZtXrAj0z2gaqfkRgLT8i6QZInW9Wb2G2enX2cmEt4MYuEF80XDEUNppl1pDhGXCJEWWRwhUJGKZsXVu7AqXaGMzlBKRFU6OxjrL0QciTXRVb6BX1VX5DlgunRPEuSeyREhh8yIeaRvrNJNFkhnZh6R7-Mq0JOU0K2Ohumq0W-V3TNGOqbBjfRhslZaBo-NxcdntqvrL1RRmkccVD8gHSIkIdg1VIqGWv7TleR8-d66h8IjSexddlfV6pZI8liNEium4D2-Dz2ztTPEGTvfg9_9r1Cd4OpldXarLs-nFATyjT0Il2wfoNXfr8hAxU1N8bM_EHzT8FFs
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Revisiting+the+mutagenicity+and+genotoxicity+of+N-nitroso+propranolol+in+bacterial+and+human+in+vitro+assays&rft.jtitle=Regulatory+toxicology+and+pharmacology&rft.au=Li%2C+Xilin&rft.au=Le%2C+Yuan&rft.au=Seo%2C+Ji-Eun&rft.au=Guo%2C+Xiaoqing&rft.date=2023-06-01&rft.pub=Elsevier+Inc&rft.issn=0273-2300&rft.eissn=1096-0295&rft.volume=141&rft_id=info:doi/10.1016%2Fj.yrtph.2023.105410&rft.externalDocID=S0273230023000788
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0273-2300&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0273-2300&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0273-2300&client=summon